🏛️ Verified NIH Record • Updated 2026-08-27

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) (NCT07489495)

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.

Who can join: Review the eligibility criteria below.

Location: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102) — Marietta, Georgia

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (82 Sites)

Showing the first 25 of 82 sites.

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102) — Marietta, Georgia
  • The West Clinic, P.C. ( Site 0115) — Germantown, Tennessee
  • Centro Oncologico Korben ( Site 0254) — CABA, Buenos Aires
  • Hospital Italiano de Buenos Aires ( Site 0253) — Ciudad de Buenos Aires, Buenos Aires
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250) — Mar del Plata, Buenos Aires
  • Centro Privado de RMI Río Cuarto S.A. II ( Site 0255) — Río Cuarto, Córdoba Province
  • Sanatorio Parque ( Site 0251) — Rosario, Santa Fe Province
  • Instituto de Oncología de Rosario ( Site 0257) — Rosario, Santa Fe Province
  • Instituto Alexander Fleming ( Site 0252) — CABA,
  • Centro Oncológico Riojano Integral ( Site 0256) — La Rioja,
  • COE (Centro Oncológico de Excelencia) ( Site 0259) — San Juan,
  • Macquarie University ( Site 2700) — Macquarie University, New South Wales
  • Princess Alexandra Hospital ( Site 2703) — Woolloongabba, Queensland
  • Peter MacCallum Cancer Centre ( Site 2702) — Melbourne, Victoria
  • CEDOES ( Site 0303) — Vitória, Espírito Santo
  • Instituto do Câncer e Transplante de Curitiba ( Site 0300) — Curitiba, Paraná
  • Liga Norte Riograndense Contra o Câncer ( Site 0307) — Natal, Rio Grande do Norte
  • Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306) — Ribeirão Preto, São Paulo
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302) — São José do Rio Preto, São Paulo
  • IC La Serena Research ( Site 0405) — La Serena, Coquimbo Region
  • Clínica Puerto Montt ( Site 0404) — Port Montt, Los Lagos Region
  • Fundacion Arturo Lopez Perez ( Site 0401) — Santiago, Region M. de Santiago
  • Bradfordhill ( Site 0400) — Santiago, Region M. de Santiago
  • ONCOCENTRO APYS ( Site 0403) — Viña del Mar, Valparaiso
  • Masarykuv onkologicky ustav ( Site 0903) — Brno, Brno-mesto

📞 Contact the Study Coordinator

Phone: (888) 577-8839

Email: Trialsites@msd.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Renal Cell

Explore by condition: All Carcinoma, Renal Cell clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗